Recent Updates
Recently added Catalysts
PCRX

Pacira BioSciences to Host Investor Day on October 15th, 2021 in Tampa, FL

Key Takeaway: TAMPA, Fla., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it will host an Investor Day on Friday, October 15, 2021, from 8:00 A
Price reaction · baseline $48.62 (2021-10-07 close) · hit after-hours · 2 other PCRX headline(s) in the window, move may be shared
day 0 close · peak
-1.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
5.7%
average across 5 past catalysts
Lead asset
FX006
Phase 2 · Osteoarthritis of the Shoulder

Full Press Release Details

TAMPA, Fla., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it will host an Investor Day on Friday, October 15, 2021, from 8:00 AM to approximately 12:00 PM ET. Key Opinion Leaders and members of the Pacira executive team will provide updates on the Company’s commercial products and pipeline opportunities. The event is taking place at The Pacira Innovation and Training Center at Tampa (the PITT). In-person attendance requires advance registration and is subject to space limitations.
An agenda as well as a live webcast of the event will be accessible through PaciraInvestorDay.com. An archived replay of the webcast will also become available through the same link following the conclusion of the event.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time. In April 2019, Pacira acquired the iovera°® system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
Last updated: Oct 8, 2021